In our study, we initially investigated the potential of TGF-β1, as well as PD-L1 and VEGF, as therapeutic targets in ccRCC, by analyzing relative expression levels of these proteins in tumors from ccRCC patients as well as in a range of ccRCC cell lines. Here, VEGFA is linked to nonpapillary renal cell carcinoma.